Activation‑induced upregulation of MMP9 in mast cells is a positive feedback mediator for mast cell activation

Xu,Lin; Cai,Zhijian; Yang,Fei; Chen,Ming

doi:10.3892/mmr.2017.6215

Activation‑induced upregulation of MMP9 in mast cells is a positive feedback mediator for mast cell activation

Authors:
- Lin Xu
- Zhijian Cai
- Fei Yang
- Ming Chen
View Affiliations

Affiliations: Department of Otolaryngology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, P.R. China, Institute of Immunology, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058, P.R. China
Published online on: February 17, 2017 https://doi.org/10.3892/mmr.2017.6215
Pages: 1759-1764

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Activated mast cells are involved in the pathogenesis of allergic rhinitis (AR). As a member of the matrix metalloproteinase (MMP) family, MMP9 has been previously demonstrated act in a pro‑inflammatory manner. Mast cells regulate the activity of MMP9, and mast cells themselves have been reported to produce MMP9. However, to the best of our knowledge, the involvement of MMP9 in mast cell activation remains to be elucidated. The present study demonstrated an upregulation of MMP9 protein and mRNA expression levels in mast cells activated by phorbol ester and ionomycin. Phosphorylated ERK and AKT protein levels also markedly increased in activated mast cells, and inhibition of the ERK and AKT signaling pathways prevented the increase of MMP9 in activated mast cells. MMP9 was demonstrated to be involved in mast cell activation, since inhibition of MMP9 activity or expression inhibited mast cell activation. Furthermore, IL‑4 treatment reduced MMP9 upregulation in activated mast cells, and interference with IL‑4 signaling with an IL‑4 neutralizing antibody promoted MMP9 upregulation in activated mast cells. These results revealed a novel MMP9‑mediated mechanism underlying mast cell activation, thus providing novel ideas for AR therapy.

View Figures

View References

1	Ridolo E, Montagni M, Melli V, Bonzano L, Incorvaia C and Canonica GW: A role for the intranasal formulation of azelastine hydrochloride/fluticasone propionate in the treatment of allergic rhinitis. Ther Deliv. 6:653–659. 2015. View Article : Google Scholar : PubMed/NCBI
2	Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, van Wijk RG, Ohta K, Zuberbier T, Schünemann HJ, et al: Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision. J Allergy Clin Immunol. 126:466–476. 2010. View Article : Google Scholar : PubMed/NCBI
3	Hadley JA, Derebery MJ and Marple BF: Comorbidities and allergic rhinitis: Not just a runny nose. J Fam Pract. 61(2 Suppl): S11–S15. 2012.PubMed/NCBI
4	Williams CM and Galli SJ: The diverse potential effector and immunoregulatory roles of mast cells in allergic disease. J Allergy Clin Immunol. 105:847–859. 2000. View Article : Google Scholar : PubMed/NCBI
5	Robbie-Ryan M and Brown M: The role of mast cells in allergy and autoimmunity. Curr Opin Immunol. 14:728–733. 2002. View Article : Google Scholar : PubMed/NCBI
6	Woolhiser MR, Okayama Y, Gilfillan AM and Metcalfe DD: IgG-dependent activation of human mast cells following up-regulation of FcgammaRI by IFN-gamma. Eur J Immunol. 31:3298–3307. 2001. View Article : Google Scholar : PubMed/NCBI
7	Wang JX, Kaieda S, Ameri S, Fishgal N, Dwyer D, Dellinger A, Kepley CL, Gurish MF and Nigrovic PA: IL-33/ST2 axis promotes mast cell survival via BCLXL. Proc Natl Acad Sci USA. 111:10281–10286. 2014. View Article : Google Scholar : PubMed/NCBI
8	Juremalm M and Nilsson G: Chemokine receptor expression by mast cells. Chem Immunol Allergy. 87:130–144. 2005. View Article : Google Scholar : PubMed/NCBI
9	Okayama Y, Saito H and Ra C: Targeting human mast cells expressing g-protein-coupled receptors in allergic diseases. Allergol Int. 57:197–203. 2008. View Article : Google Scholar : PubMed/NCBI
10	Oskeritzian CA, Price MM, Hait NC, Kapitonov D, Falanga YT, Morales JK, Ryan JJ, Milstien S and Spiegel S: Essential roles of sphingosine-1-phosphate receptor 2 in human mast cell activation, anaphylaxis, and pulmonary edema. J Exp Med. 207:465–474. 2010. View Article : Google Scholar : PubMed/NCBI
11	Bratcher PE, Weathington NM, Nick HJ, Jackson PL, Snelgrove RJ and Gaggar A: MMP-9 cleaves SP-D and abrogates its innate immune functions in vitro. PLoS One. 7:e418812012. View Article : Google Scholar : PubMed/NCBI
12	Vandenbroucke RE, Dejonckheere E and Libert C: A therapeutic role for matrix metalloproteinase inhibitors in lung diseases? Eur Respir J. 38:1200–1214. 2011. View Article : Google Scholar : PubMed/NCBI
13	Gauchotte G, Marie B, Gallet P, Nguyen DT, Grandhaye M, Jankowski R and Vignaud JM: Respiratory epithelial adenomatoid hamartoma: A poorly recognized entity with mast cell recruitment and frequently associated with nasal polyposis. Am J Surg pathol. 37:1678–1685. 2013. View Article : Google Scholar : PubMed/NCBI
14	Purwar R, Kraus M, Werfel T and Wittmann M: Modulation of keratinocyte-derived MMP-9 by IL-13: A possible role for the pathogenesis of epidermal inflammation. J Invest Dermatol. 128:59–66. 2008. View Article : Google Scholar : PubMed/NCBI
15	Abel M and Vliagoftis H: Mast cell-fibroblast interactions induce matrix metalloproteinase-9 release from fibroblasts: Role for IgE-mediated mast cell activation. J Immunol. 180:3543–3550. 2008. View Article : Google Scholar : PubMed/NCBI
16	Brower GL, Chancey AL, Thanigaraj S, Matsubara BB and Janicki JS: Cause and effect relationship between myocardial mast cell number and matrix metalloproteinase activity. Am J Physiol Heart Circ Physiol. 283:H518–H525. 2002. View Article : Google Scholar : PubMed/NCBI
17	Tchougounova E, Lundequist A, Fajardo I, Winberg JO, Abrink M and Pejler G: A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem. 280:9291–9296. 2005. View Article : Google Scholar : PubMed/NCBI
18	Abel M and Vliagoftis H: Mast cell-fibroblast interactions induce matrix metalloproteinase-9 release from fibroblasts: Role for IgE-mediated mast cell activation. J Immunol. 180:3543–3550. 2008. View Article : Google Scholar : PubMed/NCBI
19	Kanbe N, Tanaka A, Kanbe M, Itakura A, Kurosawa M and Matsuda H: Human mast cells produce matrix metalloproteinase 9. Eur J Immunol. 29:2645–2649. 1999. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Silwal P, Shin K, Choi S, Kang SW, Park JB, Lee HJ, Koo SJ, Chung KH, Namgung U, Lim K, et al: Adenine suppresses IgE-mediated mast cell activation. Mol Immunol. 65:242–249. 2015. View Article : Google Scholar : PubMed/NCBI
22	Dahiya S, Givvimani S, Bhatnagar S, Qipshidze N, Tyagi SC and Kumar A: Osteopontin-stimulated expression of matrix metalloproteinase-9 causes cardiomyopathy in the mdx model of Duchenne muscular dystrophy. J Immunol. 187:2723–2731. 2011. View Article : Google Scholar : PubMed/NCBI
23	Hyc A, Osiecka-Iwan A, Niderla-Bielinska J and Moskalewski S: Influence of LPS, TNF, TGF-ss1 and IL-4 on the expression of MMPs, TIMPs, and selected cytokines in rat synovial membranes incubated in vitro. Int J Mol Med. 27:127–137. 2011.PubMed/NCBI
24	McLeod JJ, Baker B and Ryan JJ: Mast cell production and response to IL-4 and IL-13. Cytokine. 75:57–61. 2015. View Article : Google Scholar : PubMed/NCBI
25	Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, van Weel C, et al: Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 63 Suppl 86:S86–S88. 2008. View Article : Google Scholar
26	Bernstein DI, Schwartz G and Bernstein JA: Allergic Rhinitis: Mechanisms and Treatment. Immunol Allergy Clin North Am. 36:261–278. 2016. View Article : Google Scholar : PubMed/NCBI
27	Kim HY, Nam SY, Hwang SY, Kim HM and Jeong HJ: Atractylone, an active constituent of KMP6, attenuates allergic inflammation on allergic rhinitis in vitro and in vivo models. Mol Immunol. 78:121–132. 2016. View Article : Google Scholar : PubMed/NCBI
28	Lin H, Zheng C, Li J, Yang C and Hu L: Lentiviral shRNA against KCa3.1 inhibits allergic response in allergic rhinitis and suppresses mast cell activity via PI3K/AKT signaling pathway. Sci Rep. 5:131272015. View Article : Google Scholar : PubMed/NCBI
29	Wang F, He W, Fanghui P, Wang L and Fan Q: NF-kappaBP65 promotes invasion and metastasis of oesophageal squamous cell cancer by regulating matrix metalloproteinase-9 and epithelial-to-mesenchymal transition. Cell Biol Int. 37:780–788. 2013. View Article : Google Scholar : PubMed/NCBI
30	Yu Q and Stamenkovic I: Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 14:163–176. 2000.PubMed/NCBI
31	Gupta A, Zhou CQ and Chellaiah MA: Osteopontin and MMP9: Associations with VEGF expression/secretion and angiogenesis in PC3 prostate cancer cells. Cancers (Basel). 5:617–638. 2013. View Article : Google Scholar : PubMed/NCBI
32	Yu Y, Blokhuis BR, Garssen J and Redegeld FA: Non-IgE mediated mast cell activation. Eur J Pharmacol. 778:33–43. 2016. View Article : Google Scholar : PubMed/NCBI
33	Lee CC, Huang HY and Chiang BL: Lentiviral-mediated interleukin-4 and interleukin-13 RNA interference decrease airway inflammation and hyperresponsiveness. Hum Gene Ther. 22:577–586. 2011. View Article : Google Scholar : PubMed/NCBI